Tags

Type your tag names separated by a space and hit enter

In vitro assessments of UVA protection by popular sunscreens available in the United States.
J Am Acad Dermatol. 2008 Dec; 59(6):934-42.JA

Abstract

BACKGROUND

The importance of adequate ultraviolet A (UVA) protection has become apparent with improved understanding of the mechanism of UVA-induced damage to tissues. Currently in the United States, there is no regulation on testing and labeling of sunscreens for UVA protection. In August 2007, the Food and Drug Administration (FDA) addressed this issue in a proposed rule.

OBJECTIVES

We sought to assess in vitro the degree of UVA protection provided by 13 popular sunscreen products that are commercially available in the United States.

METHOD

Thirteen sunscreen products were purchased. UVA protection of each product was measured and assessed with 3 in vitro UVA labeling indices: (1) the FDA Proposed Amendment of Final Monograph, August 27, 2007; (2) European Commission Recommendation--the Colipa and critical wavelength methods; (3) and United Kingdom's Boots star rating system.

RESULTS

Based on the new FDA-proposed guidelines, 8 products achieved the medium protection category, and 5 products achieved high protection. The latter 5 products also fulfilled the UVA protection based on the Colipa guideline desired by the European Commission Recommendation. Nine products achieved the desired critical wavelength value of 370 or higher. Based on the United Kingdom's Boots star rating system, 6 products achieved a rating of 3 stars, and the remaining 7 products achieved no star rating.

LIMITATIONS

The study only evaluated a small number of sunscreen products, and only in vitro methods were used to assess the degree of UVA protection.

CONCLUSIONS

The majority of the tested sunscreens in this study offered a medium degree of UVA protection. Compared with the sunscreens in the past, this study shows that UVA protection of sunscreens has improved. Sunscreens with avobenzone and octocrylene provided a higher degree of UVA protection. Globally, there is no uniform standard on testing and labeling sunscreens for UVA protection. In the United States, the FDA has just started to create a much-needed standard. This effort is necessary to educate the public better on how to choose products with adequate UVA protection.

Authors+Show Affiliations

Memorial Sloan-Kettering Cancer Center, New York, New York, USA. wangs@mskcc.orgNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18835064

Citation

Wang, Steven Q., et al. "In Vitro Assessments of UVA Protection By Popular Sunscreens Available in the United States." Journal of the American Academy of Dermatology, vol. 59, no. 6, 2008, pp. 934-42.
Wang SQ, Stanfield JW, Osterwalder U. In vitro assessments of UVA protection by popular sunscreens available in the United States. J Am Acad Dermatol. 2008;59(6):934-42.
Wang, S. Q., Stanfield, J. W., & Osterwalder, U. (2008). In vitro assessments of UVA protection by popular sunscreens available in the United States. Journal of the American Academy of Dermatology, 59(6), 934-42. https://doi.org/10.1016/j.jaad.2008.07.043
Wang SQ, Stanfield JW, Osterwalder U. In Vitro Assessments of UVA Protection By Popular Sunscreens Available in the United States. J Am Acad Dermatol. 2008;59(6):934-42. PubMed PMID: 18835064.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vitro assessments of UVA protection by popular sunscreens available in the United States. AU - Wang,Steven Q, AU - Stanfield,Joseph W, AU - Osterwalder,Uli, Y1 - 2008/10/02/ PY - 2008/04/13/received PY - 2008/07/23/revised PY - 2008/07/26/accepted PY - 2008/10/7/pubmed PY - 2008/12/18/medline PY - 2008/10/7/entrez SP - 934 EP - 42 JF - Journal of the American Academy of Dermatology JO - J. Am. Acad. Dermatol. VL - 59 IS - 6 N2 - BACKGROUND: The importance of adequate ultraviolet A (UVA) protection has become apparent with improved understanding of the mechanism of UVA-induced damage to tissues. Currently in the United States, there is no regulation on testing and labeling of sunscreens for UVA protection. In August 2007, the Food and Drug Administration (FDA) addressed this issue in a proposed rule. OBJECTIVES: We sought to assess in vitro the degree of UVA protection provided by 13 popular sunscreen products that are commercially available in the United States. METHOD: Thirteen sunscreen products were purchased. UVA protection of each product was measured and assessed with 3 in vitro UVA labeling indices: (1) the FDA Proposed Amendment of Final Monograph, August 27, 2007; (2) European Commission Recommendation--the Colipa and critical wavelength methods; (3) and United Kingdom's Boots star rating system. RESULTS: Based on the new FDA-proposed guidelines, 8 products achieved the medium protection category, and 5 products achieved high protection. The latter 5 products also fulfilled the UVA protection based on the Colipa guideline desired by the European Commission Recommendation. Nine products achieved the desired critical wavelength value of 370 or higher. Based on the United Kingdom's Boots star rating system, 6 products achieved a rating of 3 stars, and the remaining 7 products achieved no star rating. LIMITATIONS: The study only evaluated a small number of sunscreen products, and only in vitro methods were used to assess the degree of UVA protection. CONCLUSIONS: The majority of the tested sunscreens in this study offered a medium degree of UVA protection. Compared with the sunscreens in the past, this study shows that UVA protection of sunscreens has improved. Sunscreens with avobenzone and octocrylene provided a higher degree of UVA protection. Globally, there is no uniform standard on testing and labeling sunscreens for UVA protection. In the United States, the FDA has just started to create a much-needed standard. This effort is necessary to educate the public better on how to choose products with adequate UVA protection. SN - 1097-6787 UR - https://www.unboundmedicine.com/medline/citation/18835064/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0190-9622(08)00934-1 DB - PRIME DP - Unbound Medicine ER -